



☐ ☐ ☐ ☐ ☐ ☐
☐ ☐ ☐ ☐ ☐
☐ ☐ ☐
☐ ☐ ☐ ☐ ☐ ☐

How To Check if
a Medicine or Supplement Has Aspirin, Other NSAIDs, Vitamin E, or Fish Oil
(www.mskcc.org/cancer-care/patient-education/common-medications-containing-aspirin-and-other-nonsteroidal-anti-inflammatory-drugs-nsaids)
Herbal
Remedies and Cancer Treatment(www.mskcc.org/cancer-care/patient-education/herbal-remedies-and-treatment)

[illegible]

GLP-1

1. 2023年12月31日，公司总资产为100,000,000.00元，其中流动资产为80,000,000.00元，非流动资产为20,000,000.00元。

- [illegible]

■■■■ ■■■■■ ■■■, *Eating and Drinking Before Your Surgery or Procedure When Taking GLP-1 Medicines* (www.mskcc.org/cancer-care/patient-education/eating-and-drinking-before-your-surgery-or-procedure-when-taking-glp-1-medicines)
■■■■■■■ |

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications used to treat type 2 diabetes. They work by mimicking the action of the hormone GLP-1, which helps to lower blood sugar levels by stimulating the release of insulin from the pancreas and reducing the production of glucose in the liver. GLP-1 RAs also have other beneficial effects, such as slowing down gastric emptying and promoting satiety, which can help with weight management. Common side effects include nausea, vomiting, and constipation, but these are usually mild and temporary. GLP-1 RAs are generally well-tolerated and have a low risk of hypoglycemia when used in combination with other diabetes medications. They are often prescribed as an add-on therapy to insulin or other oral diabetes medications. Examples of GLP-1 RAs include semaglutide, liraglutide, and dulaglutide.

• 睡眠呼吸暂停综合征 (阻塞性睡眠呼吸暂停综合征®, 中枢性睡眠呼吸暂停综合征®) • 睡眠呼吸暂停综合征 (阻塞性睡眠呼吸暂停综合征®)	• 睡眠呼吸暂停综合征 (阻塞性睡眠呼吸暂停综合征®, 中枢性睡眠呼吸暂停综合征®) • 睡眠呼吸暂停综合征 (阻塞性睡眠呼吸暂停综合征®, 中枢性睡眠呼吸暂停综合征®)
--	---

睡眠呼吸暂停综合征

睡眠呼吸暂停综合征是指睡眠过程中反复出现的呼吸暂停或低通气，导致血氧饱和度下降，进而引起一系列临床症状。该病可分为阻塞性睡眠呼吸暂停综合征（OSA）和中枢性睡眠呼吸暂停综合征（CSA）。OSA是由于上呼吸道狭窄或阻塞所致，而CSA则是由于呼吸中枢功能障碍所致。该病的诊断通常需要通过多导睡眠监测（PSG）来确认。治疗方面，OSA患者可采用持续气道正压通气（CPAP）治疗，而CSA患者则可能需要使用双水平气道正压通气（BiPAP）或药物治疗。

OSA患者常表现为夜间打鼾、呼吸暂停、憋醒、晨起头痛、白天嗜睡等症状。长期未治疗的OSA可导致高血压、冠心病、糖尿病、脑卒中等多种并发症。因此，对于疑似OSA的患者，应及时就医并进行相关检查。CPAP治疗是目前OSA的一线治疗方法，能够有效改善呼吸暂停，提高睡眠质量，并降低相关并发症的风险。

睡眠呼吸暂停综合征的诊断与治疗

睡眠呼吸暂停综合征的诊断主要依据临床症状和睡眠监测结果。多导睡眠监测（PSG）是诊断的金标准，能够记录睡眠过程中的呼吸、心率、血氧饱和度等多种生理指标。对于轻中度OSA患者，家庭睡眠监测（HSAT）也是一种可行的诊断方法。治疗方面，除了CPAP和BiPAP等无创通气治疗外，对于部分患者，手术切除多余组织（如鼻中隔偏曲、扁桃体肥大等）也是一种选择。此外，生活方式的改变，如戒烟、减肥、侧卧睡眠等，也有助于改善病情。

睡眠呼吸暂停综合征是一种可治疗的疾病，通过规范的治疗和生活方式的调整，患者可以显著改善症状，提高生活质量。建议患者在医生的指导下进行个体化的治疗方案。

The information on this page is for informational purposes only. It is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this page.

For more information, please contact the National Cancer Institute (NCI) at 1-800-4-A-CANCER (1-800-422-6237) or the National Cancer Institute's Cancer Information Service (CIS) at 1-800-4-CANCER (1-800-422-6237).

The information on this page is for informational purposes only. It is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this page.

The information on this page is for informational purposes only. It is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this page.

The information on this page is for informational purposes only. It is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this page.

- For more information, please contact the National Cancer Institute (NCI) at 1-800-4-A-CANCER (1-800-422-6237) or the National Cancer Institute's Cancer Information Service (CIS) at 1-800-4-CANCER (1-800-422-6237). *Advance Care Planning for People With Cancer and Their Loved Ones* (www.mskcc.org/cancer-care/patient-education/advance-care-planning)
- For more information, please contact the National Cancer Institute (NCI) at 1-800-4-A-CANCER (1-800-422-6237) or the National Cancer Institute's Cancer Information Service (CIS) at 1-800-4-CANCER (1-800-422-6237). *How*

[illegible][illegible][illegible][illegible]

■■■■■ .

- 1275 (PSC) 67 68

1275 (PSC) 67 68

1275 (PSC) 67 68

██████████ ██████████, ████████████████████ B ██████████ (██████████████████)
██████ |

- ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ .**

- MSK www.msk.org/parking

000 0000000 00000 00000 0000 00000000 0000000 00 0000
 00000 00 00000 00000 000000000 00000 000000 0000 000000
 000000 00, 0000 00000 00000 000 0000 0000 | 000000 00
 0000 , 000 0000000 0000 00000000000 000000 9 0000 0000
 00000 5 0000 0000 000000000 00000000 00 | 00000 5 0000 0000
 00000, 00000-000000 000000 0000 0000000000 000000 0000000
 00000 00 00000 212-639-2000 '000 0000 0000 | 0000000 0000
 00 00000000000 00000 0000000000 00 00000000 00 0000
 0000000 0000 00000 0000 00 0000 |

0000-0000 0000 0000 0000 0000 0000 0000
00000000 000000 000000 00 00000 000000000 00 0000000
0000 |

[illegible]

■■■■ ■■■■■■■■ ■■■■■■ ■■■■■■■■ ■■■■■■■■■■ ■■ ■■■■■■■■■■ ■■■■■■
 ■■■■■■ ■■■■ ■■ ■■■■■ ■■, ■■■■ ■■■■■■■■■■ ■■■■■■■ ■■■■ 1
 ■■■■ ■■■■■■■■ ■■ ■■■■■■■■ ■■■■■■ ■■■■■■■■ | ■■■■■■■■
 ■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■ ■■■■■■■■ ■■■■ |

[illegible][illegible]

- [illegible]

[illegible]

Important Information: If you are taking a GLP-1 medicine, you may need to stop taking it before surgery or a procedure. This is because GLP-1 medicines can slow down your stomach's emptying. This can increase the risk of complications during surgery or a procedure. For more information, see the *Eating and Drinking Before Your Surgery or Procedure When Taking GLP-1 Medicines* (www.mskcc.org/cancer-care/patient-education/eating-and-drinking-before-your-surgery-or-procedure-when-taking-glp-1-medicines) or ask your healthcare provider.



You may be asked to stop taking your GLP-1 medicine 12 hours before surgery or a procedure. This is because GLP-1 medicines can slow down your stomach's emptying. This can increase the risk of complications during surgery or a procedure.

Some GLP-1 medicines may be stopped 24 hours before surgery or a procedure. This is because some GLP-1 medicines can slow down your stomach's emptying for a longer period of time. Your healthcare provider will tell you when to stop taking your GLP-1 medicine. If you are taking a GLP-1 medicine, you may need to stop taking it before surgery or a procedure. This is because GLP-1 medicines can slow down your stomach's emptying. This can increase the risk of complications during surgery or a procedure.

What to Do Before Surgery or a Procedure

1. Stop taking your GLP-1 medicine 12 hours before surgery or a procedure. If you are taking a GLP-1 medicine, you may need to stop taking it before surgery or a procedure. This is because GLP-1 medicines can slow down your stomach's emptying. This can increase the risk of complications during surgery or a procedure.

What to Do After Surgery or a Procedure

A red prohibition sign (a circle with a diagonal slash) over a stylized illustration of a glass, a fork, and a knife, indicating that eating and drinking are prohibited.

XXXXXXXXXX XXXXXXXX XXXXXXX XXXXXXX XXXXX XXXXXXX XX,
XX XXXXXXX XXXXXXX XXXXXXXXXX XXXXXXXXXX

[illegible]

██████████ ██████████ ██████████, ██████████ 4% CHG ██████████ ██████████
██████████ ██████████ ██████████ ██████████ ██████████ ██████████ (██████████
██████████ ██████████ ██████████) ██████████ ██████████ ██████████ ██████████

■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■

- 11/15

888-675-7722

[illegible]

646-227-3378

2023 年 12 月 31 日，公司总资产 1,000,000,000.00 元，总负债 400,000,000.00 元，所有者权益 600,000,000.00 元。2024 年 1 月 1 日，公司总资产 1,000,000,000.00 元，总负债 400,000,000.00 元，所有者权益 600,000,000.00 元。2024 年 1 月 1 日至 2024 年 12 月 31 日止，公司总资产 1,000,000,000.00 元，总负债 400,000,000.00 元，所有者权益 600,000,000.00 元。

■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■

212-639-7202

[illegible]

646-357-9272

[illegible]

MSK is a leading provider of cancer care and research. We are committed to providing the best possible care for our patients. Our team of experts is dedicated to understanding the unique needs of each patient and providing personalized treatment plans. We are currently conducting a clinical trial for a new treatment for breast cancer. The trial is open to patients who are 18 years of age or older and have been diagnosed with breast cancer. For more information, please contact our research coordinator at 212-639-2000 or visit our website at www.mskcc.org/pe.

MSK is a leading provider of cancer care and research. We are committed to providing the best possible care for our patients. Our team of experts is dedicated to understanding the unique needs of each patient and providing personalized treatment plans. We are currently conducting a clinical trial for a new treatment for breast cancer. The trial is open to patients who are 18 years of age or older and have been diagnosed with breast cancer. For more information, please contact our research coordinator at 212-639-2000 or visit our website at www.mskcc.org/pe.

Getting Ready for Surgery - Last updated on March 5, 2026

MSK is a leading provider of cancer care and research. We are committed to providing the best possible care for our patients. Our team of experts is dedicated to understanding the unique needs of each patient and providing personalized treatment plans. We are currently conducting a clinical trial for a new treatment for breast cancer. The trial is open to patients who are 18 years of age or older and have been diagnosed with breast cancer. For more information, please contact our research coordinator at 212-639-2000 or visit our website at www.mskcc.org/pe.